Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Medivir","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"A Joint Patent Application For MALT1 Inhibitors Published","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Cryostem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rheos Medicines Forms Research Collaboration With CRYOSTEM to Evaluate MALT1\u2011Targeted Therapeutics for Graft-versus-Host-Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rheos Medicines Presents Data Demonstrating Potential of MALT1 Inhibition as Novel Approach for the Treatment of Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rheos Medicines to Present Data at ASH 2021 for MALT1 Inhibition for Treatment of Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rheos Medicines Presents New Data Supporting MALT1 Inhibition as Novel Strategy for Precision Medicine-Based Approach to Treating Chronic Graft-Versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rheos Medicines Announces Publication of New Data to Support Targeting MALT1 to Treat Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Rheos Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rheos Medicines Receives FDA \u201cStudy May Proceed\u201d Letter to Initiate Phase 1 Clinical Study Under its Investigational New Drug Application for RHX-317 for Treatment of Autoimmune and Inflammatory Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Rheos Medicines

    Menu

    Rheos Medicines

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Rheos Medicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rheos Medicines Receives FDA “Study May Proceed” Letter to Initiate Phase 1 Clinical Study Under its Investigational New Drug Application for RHX-317 for Treatment of A...

              Details:

              A MALT1 inhibitor, RHX-317 is designed to inhibit the activity of multiple immune cell types, attenuating the inflammatory response in the activated immune system, for the treatment of autoimmune and inflammatory diseases.

              Lead Product(s): RHX-317

              Therapeutic Area: Immunology Product Name: RHX-317

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rheos Medicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rheos Medicines Announces Publication of New Data to Support Targeting MALT1 to Treat Autoimmune and Inflammatory Diseases

              Details:

              RHX-317 targets MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), a protein expressed exclusively in cells of immune system, designed to inhibit activity of multiple immune cell types, attenuating the inflammatory response in activated immune system.

              Lead Product(s): RHX-317

              Therapeutic Area: Immunology Product Name: RHX-317

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rheos Medicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rheos Medicines Presents New Data Supporting MALT1 Inhibition as Novel Strategy for Precision Medicine-Based Approach to Treating Chronic Graft-Versus-Host Disease

              Details:

              RHX-317, is a novel, small molecule MALT1 inhibitor initially in development for the treatment of chronic GVHD. Preclinical data demonstrate MALT1 inhibition targets pathogenic activity of the activated immune system, showing efficacy in a model of cGVHD.

              Lead Product(s): RHX-317

              Therapeutic Area: Immunology Product Name: RHX-317

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rheos Medicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rheos Medicines to Present Data at ASH 2021 for MALT1 Inhibition for Treatment of Graft-Versus-Host Disease

              Details:

              Rheos Medicines will present preclinical data showing the potential of RHX-317, a MALT1 inhibitors for the treatment of chronic Graft-Versus-Host Disease (GVHD) at the 63rd Annual Meeting of the American Society of Hematology.

              Lead Product(s): RHX-317

              Therapeutic Area: Immunology Product Name: RHX-317

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rheos Medicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rheos Medicines Presents Data Demonstrating Potential of MALT1 Inhibition as Novel Approach for the Treatment of Autoimmune and Inflammatory Diseases

              Details:

              The results demonstrating MALT1 inhibition support Rheos’s lead product candidate, RHX-317, a novel, small molecule MALT1 inhibitor, that the company is initially developing for the treatment of chronic graft versus host disease (GVHD).

              Lead Product(s): RHX-317

              Therapeutic Area: Immunology Product Name: RHX-317

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rheos Medicines

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Rheos Medicines Forms Research Collaboration With CRYOSTEM to Evaluate MALT1‑Targeted Therapeutics for Graft-versus-Host-Disease

              Details:

              The goal of the collaboration is to provide biological resources from HSC patients in order to evaluate MALT1-targeted therapeutics, including Rheos’s lead product candidate, RHX-317, for Graft-versus-Host Disease, based on functional immunologic profiling of patients.

              Lead Product(s): RHX-317

              Therapeutic Area: Immunology Product Name: RHX-317

              Highest Development Status: IND Enabling Product Type: Small molecule

              Recipient: Cryostem

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Rheos Medicines

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              A Joint Patent Application For MALT1 Inhibitors Published

              Details:

              The patent application is an outcome of the option agreement that was previously entered into between the two companies regarding Medivir’s preclinical MALT1 project.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Recipient: Medivir

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY